In Brief: International Murex Technologies
This article was originally published in The Gray Sheet
Executive Summary
International Murex Technologies: Commences overseas launch of its second-generation enzyme immunoassay for serological genotyping of Hepatitis C (HCV). The test which identifies whether a patient is infected with HCV types 1-6, will be marketed to "leading diagnostic laboratories," Murex says. The firm notes that the "sale of this test is not currently affected by injunctions blocking Murex from manufacturing and selling its Anti-HCV test." Murex has been enjoined from making and selling HCV assays by a German court because the products infringe German and European patents held by Chiron ("The Gray Sheet" Jan. 2, In Brief)...